Semaglutide SM30 30mg*10vials

Semaglutide SM30 (30mg x 10 vials) is the top-of-the-line upgraded flagship version of the Semaglutide SM series. It is a high-purity, ultra-stable, long-acting lyophilized GLP-1 receptor agonist peptide suitable for cutting-edge preclinical metabolic studies. As the final iteration of SM10, SM15, and SM20, SM30 utilizes third-generation whole-molecule optimization technology, achieving saturated target binding efficiency, superior anti-degradation properties, and extended in vivo activity retention. Its ultra-high concentration of 30mg per vial makes it perfectly suited for ultra-high dose gradient experiments, ultra-long-term metabolic modeling, large-scale batch replication validation, and extreme phenotypic mechanism studies. It is a high-quality core research ingredient for high-standard in-depth GLP-1 mechanism exploration and extreme dose-efficacy boundary studies.

Product Function and Research Value

Semaglutide SM30 possesses a full-effect GLP-1 single-target activation effect, stably and efficiently mimicking the body's physiological incretin activity. In advanced laboratory research, it is primarily used to explore the repair of extreme insulin resistance, long-term stable regulation of blood glucose homeostasis, and comprehensive remodeling of glucose and lipid metabolism pathways. It exhibits stronger appetite suppression and extended satiety maintenance, effectively reducing energy intake and providing deep intervention for systemic lipid metabolism disorders and refractory fat accumulation. Compared to accumulation mechanisms, conventional versions such as SM10, SM15, and SM20 possess more saturated biological activity, more extreme experimental phenotypes, and more durable therapeutic stability, providing ultra-precise and highly reliable data support for cutting-edge research on severe refractory metabolic diseases, advanced endocrine regulatory mechanisms, and the validation of extreme dose-response relationships.

Core Product Advantages

1. SM30 Top-Tier Ultimate Upgrade: A fully optimized third-generation molecular structure with saturated target binding capacity. Its biological activity, molecular stability, and anti-attenuation capabilities comprehensively surpass ordinary semaglutide and all lower-version SM series products, perfectly meeting the stringent standards of high-end cutting-edge scientific research. 2. 30mg Ultra-High Concentration Upper Limit: The highest specification of the SM series flagship product, with a concentration 3 times that of the conventional 10mg, 2 times that of 15mg, and 1.5 times that of 20mg. Perfectly suitable for ultra-high dose gradient extreme control experiments, ultra-long-term repeated animal models, and large-scale multi-group parallel experiments, eliminating data deviations caused by frequent dilution and solution changes.

3. Advanced Full-Lock Lyophilization Process: Utilizes pharmaceutical-grade aseptic vacuum lyophilization technology to completely lock in the molecular activity of the peptide. Each batch undergoes rigorous full-category high-performance liquid chromatography (HPLC) purity testing and comes with a complete official Certificate of Account (COA). Impurity residues are extremely low, and batch-to-batch variability is zero.

4. Standardized 10-bottle Bulk Packaging: Each box contains 10 bottles in integrated aseptic packaging, ideal for long-term strategic reserves in laboratories, core preclinical research and development of top-tier drugs, key university research projects, and large-scale global wholesale procurement.

Simegrapeptide (SM30) 30mg*10 bottles is the flagship product of the Simegrapeptide SM series. It is a high-purity, ultra-stable, long-acting lyophilized research peptide of GLP-1 receptor agonist, designed specifically for cutting-edge metabolic research. As the final iteration of the SM10, SM15, and SM20 series, SM30 incorporates third-generation global molecular optimization technology, achieving target binding saturation, extreme anti-degradation performance, and ultra-long-lasting in vivo activity maintenance. With a maximum concentration of 30mg per vial, it is perfectly suited for ultra-high dose gradient experiments, ultra-long-term metabolic modeling, large-scale repeated validation, and extreme phenotypic mechanism studies. It is a top-tier core ingredient for in-depth research into GLP-1 mechanisms and pharmacodynamic limits.

Core Uses and Research Value of the Peptide: SM30 possesses full-efficiency GLP-1 single-target activation capability, efficiently and stably mimicking the physiological effects of incretin in vivo, making it suitable for various high-end research scenarios. It is primarily used for in-depth research into the repair mechanisms of extreme insulin resistance, long-term stable regulation of blood glucose homeostasis, and the remodeling of the entire glucose and lipid metabolic pathway. It also has e